News und Analysen
QIAGEN N.V. to hold investor call on Wednesday, October 28, after releasing results for Q3 2020 and first nine months of 2020
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced it would hold a conference call on Wednesday, October 28, after releasing full results for the third quarter and first nine
Agreement with UCHealth Expands Humana’s Medicare Advantage Provider Network in the Rocky Mountain Region
UCHealth and Humana Inc. (NYSE: HUM), a leading health and well-being company, have signed an in-network agreement for UCHealth University of Colorado Hospital on the Anschutz Medical Campus in
VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, And Announces the Initiation of The Phase II Clinical Study HEART
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating
QIAGEN meldet starke Ergebnisse für das dritte Quartal und die ersten neun Monate 2020 und hebt Ausblick für das Gesamtjahr 2020 an
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute starke, vollständige Ergebnisse der operativen Tätigkeit für das dritte Quartal und die ersten neun Monate 2020 bekannt, sowie die
QIAGEN Reports Strong Results for Third Quarter and First Nine Months of 2020 and Increases Outlook for Full-Year 2020
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced strong full results of operations for the third quarter and first nine months of 2020 and also increased its outlook for net sales
First Approved Cancer Treatment for TGCT Included DILIsym Simulations in FDA Review
DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software for pharmaceutical safety and efficacy, today announced that simulations
Veeva Teams with Life Sciences to Offer Industrywide Source for Key Contacts, Information, and Services from Across Companies and Brands
To help healthcare professionals (HCPs) get provider and patient resources faster, Veeva Systems (NYSE: VEEV), in partnership with the industry, today introduced MyVeeva for Doctors, a mobile
Veeva Teams with Life Sciences to Offer Industrywide Source for Key Contacts, Information, and Services from Across Companies and Brands
To help healthcare professionals (HCPs) get provider and patient resources faster, Veeva Systems (NYSE:VEEV), in partnership with the industry, today introduced MyVeeva for Doctors, a mobile
PFIZER REPORTS THIRD-QUARTER 2020 RESULTS
Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2020 and updated and tightened certain components of Total Company(3) 2020 financial guidance, which continues to reflect actual
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Priority Review designation to the company’s New Drug Application (NDA) for
Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announced the detailed results from
Sensorion and Novasep Announce Signature of a Gene Therapy Product Development and Manufacturing Agreement
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Dexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue
DexCom, Inc. (NASDAQ:DXCM) today announced that Rick Doubleday, Executive Vice President and Chief Commercial Officer, will retire at the end of 2020 in order to spend more time with his family
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.19 per share of Class A common stock issued and
PerkinElmer erhält CE-Kennzeichnung für auf Atemwegsinfektionen, einschließlich COVID-19, ausgerichtetes Multi-Analyt-Panel
PerkinElmer, Inc. (NYSE: PKI) meldete heute, dass sein PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel die Zulassung für die Vermarktung als In-vitro-Diagnostikum (IVD) in mehr als 30 Ländern im Sinne
ProvideGx® and Baxter Healthcare Secure the Supply of Critical Shortage Drug for COVID-19 Patients Requiring Ventilation
Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Baxter Healthcare to supply pre-filled, single-use IV bags of dexmedetomidine hydrochloride to healthcare providers
Bayer kauft Asklepios: Wird jetzt alles besser?
Schon seit vielen Monaten steht die Aktie des Leverkusener Chemie- und Pharmagiganten Bayer (WKN: BAY001) unter Abgabedruck. Grund hierfür ist natürlich die leider völlig verkorkste
PerkinElmer Receives CE Mark for Multi-analyte Respiratory Panel Including COVID-19
PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnostic (IVD) device in more than 30
CO.DON AG: Erste Spherox Transplantation in der Schweiz erfolgreich durchgeführt
Berlin / Teltow / Leipzig, 26.10.2020 – Am Inselspital Bern, einem der führenden orthopädischen Zentren der Schweiz, wurde der erste Patient mit dem körpereigenen Knorpelzelltransplantat
Performance-Roundup: NBC-Empfehlung mit +543%; weitere Aktien im Fokus
Im Vorfeld der US-Präsidentschaftswahlen und mitten in der zweiten, voraussichtlich noch deutlich heftigeren Corona-Welle bleiben die Märkte erwartungsgemäß hochvolatil. Zwar hat die Pandemie bei
Sirona Biochems klinische Studie zu TFC-1067 zur Veröffentlichung im Journal of Cosmetic Dermatology angenommen
Vancouver, Kanada – 26. Oktober 2020 – Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (US-OTC: SRBCF) („Sirona“) freut sich bekannt zu geben, dass die von Dr. Zoe Draelos von der Firma
Sirona Biochem Announces Acceptance of Clinical Study for TFC-1067 in the Journal of Cosmetic Dermatology
Vancouver, Canada – October 26, 2020 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce that the clinical study using .2% TFC-1067 and conducted
NANOBIOTIX Provides Updates on Global Clinical Development Plan for First-in-class Radioenhancer NBTXR3 at ASTRO 2020
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005205/en/
Pipeline Visualization (Photo: Business Wire)
Nanobiotix Announces Third Quarter 2020 Revenue
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of
True Leaf meldet Zustimmung der Gläubiger zu den Vorschlägen
Das Unternehmen erreicht einen wichtigen Schritt für den Ausstieg aus dem Gläubigerschutz und die Unternehmensumstrukturierung
Vernon (British Columbia), 23. Oktober 2020. True Leaf